Biohaven Pharmaceutical Holding Company Ltd

NYSE:BHVN   3:59:54 PM EDT
+0.74 (+0.52%)
Earnings Announcements, Mergers / Acquisitions

Pfizer To Acquire Biohaven Pharmaceuticals

Published: 05/10/2022 11:04 GMT
Biohaven Pharmaceutical Holding Company Ltd (BHVN) - Pfizer to Acquire Biohaven Pharmaceuticals.
Pfizer Inc - Pfizer Will Pay Transaction Consideration Totaling Approximately $11.6 Billion in Cash.
Pfizer Inc - Biohaven Common Shareholders Will Receive $148.50 per Biohaven Share in Cash.
Pfizer Inc - Pfizer Expects to Finance Transaction With Existing Cash on Hand.
Pfizer Inc - Biohaven Shareholders Will Receive Plus 0.5 of a Share of New Publicly Traded Company That Retains Biohaven's Non-cgrp Pipeline Compounds.
Pfizer Inc - Co Will Make Payments to Settle Biohaven's Third Party Debt and for Redemption of All Outstanding Shares of Redeemable Preferred Stock.
Pfizer Inc - Biohaven Will Not Hold a Conference Call to Discuss Its Q1 2022 Financial Results.
Pfizer Inc - Pfizer's Acquisition of Biohaven is Subject to Completion of New Biohaven Spin-off Transaction.
Pfizer - New Biohaven to Have Right to Get Tiered Royalties From Co on Any Annual Net Sales of Rimegepant & Zavegepant in U.S. in Excess of $5.25 Billion.
Revenue is expected to be $209.42 Million
Adjusted EPS is expected to be -$2.58

Next Quarter Revenue Guidance is expected to be $241.4 Million
Next Quarter EPS Guidance is expected to be -$2.15

More details on our Analysts Page.